Summary Chaetoglobosin K (ChK) is a natural product that inhibits anchorage-dependent and anchorageindependent growth of ras-transformed cells, prevents tumor-promoter disruption of cell-cell communication, and reduces Akt activation in tumorigenic cells. This study demonstrates how ChK modulates the JNK pathway in ras-transformed and human lung carcinoma cells and investigates regulatory mechanisms controlling ChK's effect on the Akt and JNK signaling pathways. Human lung carcinoma and ras-transformed epithelial cell lines treated with ChK or vehicle for varying times were assayed for cell growth or extracted for total proteins for western blot analysis using phosphorylation site-specific antibodies to monitor changes in activation of JNK, Akt, and other signaling enzymes. Results show that ChK inhibited both Akt and JNK phosphorylation at key activation sites in ras-transformed cells as well as human lung carcinoma cells. Downstream effectors of both kinases were accordingly affected. Direct upstream kinases of JNK were not affected by ChK. Wortmannin and LY294002, two PI3 kinase inhibitors, inhibited Akt but not JNK phosphorylation in ras-transformed cells. This report establishes the dual inhibitory effect of ChK on both the Akt and JNK signaling pathways in ras-transformed epithelial and human carcinoma cells. The unique effect of ChK on these two key pathways involved in carcinogenesis earmarks ChK for further studies to determine its molecular target(s) and in vivo anti-tumor potential.
Introduction
There have been many challenges in creating effective therapies to inhibit growth of cancer cells, in part because of a lack of selectivity between dividing normal and cancer cells. Persistent activation of cellular signaling pathways by oncogenes results in disruption of normal growth control and can lead to neoplastic transformation. Targeted anti-tumor therapy is based on the hypothesis that inhibition of these constitutively turned on key signaling pathways will control tumor cell growth by altering the phenotype of the particular tumor cell, while minimizing effects on cells in which these signaling pathways are not dominant. This hypothesis is supported by numerous tumor cell model systems in which inhibition of oncogenic signaling pathways reduces cell growth, decreases tumorigenicity of treated cells, and at least partially reverses the transformed phenotype. Examples include inhibition of src, ras neu, and myc oncogene signaling pathways, among others [1] [2] [3] [4] . While substantial progress has been made in developing drugs that target overactive oncogenic pathways, current therapies are often limited to one or a few types of cancer and most have limited effectiveness in extending survival times [5] [6] [7] [8] [9] [10] [11] [12] . Thus, additional therapies are needed to target other cancer types and with greater effectiveness.
The Ras-activated PI3 kinase (PI3K) pathway is an important regulator of cell proliferation and survival. When over stimulated, it has been shown to lead to neoplastic transformation [13] [14] [15] . An important downstream effector of PI3K is Akt (also called PKB), a PIP3-and phosphorylation-activated serine-threonine kinase that phosphorylates several intracellular targets involved in cell proliferation and survival such as GSK-3α, FKHD, and MDM2 [14, [16] [17] [18] . Activation of Akt/PKB has been reported to be frequently elevated in human cancers and constitutive activation of this kinase was required for oncogenic transformation in NIH 3T3 cells [19] . Elevated activation of Akt has also been linked to skin tumorigenesis [20, 21] . In addition, phosphorylation of Akt on serine 473 was shown to be increased in poorly differentiated prostate cancer cells [22] and phosphorylation on this residue is also a good predictor of poor clinical outcome in cancer patients [23] . Results from these and other studies contribute to Akt's current status as a cancer biomarker and target for development of novel human cancer therapies.
The stress-activated protein kinase pathway, JNK, alternatively referred to as SAPK/JNK, also plays important roles in control of cell proliferation in a wide variety of cell types. Elevated JNK activation has been shown to contribute to the pathogenesis of human brain tumors [24] . Activated JNK may act as an oncoprotein through its abilities to activate the transcription factor component c-JUN, or inactivate the proapoptotic protein BAD [25] . More recently, Khatlani, et al. [26] showed that JNK is activated in a significant subset of nonsmall-cell lung carcinoma biopsies, and can promote neoplastic transformation in normal human bronchial epithelial cells. Thus, reduced activation of JNK could be beneficial in controlling growth in tumors expressing over-activated JNK.
Chaetoglobosin K (ChK) is a bioactive natural product cytochalasin derived from Diplodia macrospora [27] that has been shown to promote apoptosis and inhibit cytokinesis in ras-transformed cells [28, 29] as well as prevent tumor promoter induced inhibition of gap junction-mediated cellular communication [30, 31] . ChK was also shown to reduce Akt phosphorylation at two activation sites in rastransformed cells [29] . We now demonstrate dual inhibition by ChK of both Akt and JNK activation in ras-transformed epithelial and human lung carcinoma cells. To our knowledge, this is the first study to demonstrate inhibition of both of these oncogenic signaling pathways by a single compound. This unique dual effect of ChK on these key signaling pathways involved in carcinogenesis underscores its potential as a targeted anti-tumor therapy.
Materials and methods

Materials
WB-ras cells were derived from WB-F344 rat liver epithelial cells and were obtained from James Trosko at Michigan State University. H2009 and H1299 human lung tumor cells were from the American Type Culture Collection (ATCC, Manassas, VA) and provided by Randall Ruch at the University of Toledo and Nader Moniri at Mercer University, respectively. Chaetoglobosin K was purified from Diplodia macrospora at >97 % pure [27] , MO) . JNK, Akt, PTEN, PDK1, MKK4, MKK7, c-JUN, ATF-2, and phospho-JNK (thr183/tyr185), phospho-Akt (ser473), phospho-PTEN (ser308/thr382,383), phospho-PDK1 (ser241), phospho MKK4 (thr261), phospho-MKK7 (ser271/thr275), phosphoc-JUN (ser63), phospho-ATF2 (thr71), phospho-MDM2 (ser166), phospho-Stat3 (ser727), phospho-Rac1(ser71), β-actin, α-tubulin, anti-rabbit IgG alkaline phosphataseconjugated antibodies and LY294002 were purchased from Cell Signaling Technology (Beverly, MA). Tween-20, TrisHCl, DC Protein Assay, SDS, nonfat dry milk, 25x alkaline phosphatase color development buffer, 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium (BCIP/NBT), protein molecular mass standards, PVDF membranes and all electrophoresis and transfer buffer components were from Bio-Rad (Hercules, CA). All other chemicals, reagents, and solvents used were of analytical grade.
Methods
Cell culture
Human lung carcinoma cells (H2009 or H1299) were grown in RPMI-1640 media supplemented with 2 mM/L Lglutamine and 10 % fetal bovine serum and used between passages 38-55 for H2009 and 5-10 for H1299. WB-ras rat liver epithelial cells were subcloned from single cells to obtain the WB-ras1 line, grown in alpha Modification of Eagle's Media supplemented with 2 mM/L l-glutamine and 5 % FBS, and used for experiments between passages 3 and 18. G418 antibiotic was added to the α-MEM for culturing cells at a concentration of 500 μM, but was not added to cells plated for experiments. Confluent cells were subcultured by trypsinization and plated at 5-20 % confluence. Cells were incubated in an atmosphere of 5 % CO 2 at 37°C.
Cell growth assay
H2009 human lung carcinoma cells were plated at 5-10 % confluence onto 35 mm 2 dishes, initial plating densities quantified, culture medium added to 2 mL, and allowed to attach overnight. Cells were treated with varying concentrations of vehicle (DMSO) or ChK in DMSO and incubated at 37°C for varying times. The DMSO concentration was kept below 1 %. Following the desired incubation time, medium was removed and cells were washed twice with PBS. 0.2 ml of 0.25 % trypsin solution and 0.8 ml of PBS were added and cells incubated until they detached from the dish, followed by addition of 1 ml of PBS containing 0.1 mM CaCl 2 and 0.1 mM MgCl 2 . Cells in suspension were counted as is or after dilution with 2-5 ml as needed of PBS, using a hemocytometer to determine the number of cells per dish. Triplicate or quadruplicate dishes were counted for each time point.
Protein concentration assay
Protein concentrations were determined using the Bio-Rad DC protein assay. BSA was used as a standard protein and absorbances were read at 750 nm using a Tecan plate reader.
Western immunoblot assay
Human lung carcinoma cells and WB-ras1 were grown to 85-95 % confluence in 25 cm 2 flasks, washed with 10 ml of PBS and extracted with 250 μl 2 % SDS, 1 mM PMSF, and 1:100 dilution of protease inhibitor cocktail. Lysed cells were scraped, suspensions transferred to microcentrifuge tubes, and samples sonicated for two, 15 s pulses at room temperature. 4x Laemmli sample buffer was added to equal amounts of protein/lane at 25 % final sample volume, proteins separated on 12.0 % acrylamide SDS gels, and transferred to PVDF membranes by wet transfer overnight at 20 V or semi-dry transfer for 7 min using a Bio-Rad Trans-Blot Turbo. Membranes were washed with H 2 O, stained with Ponceau Red for 2-3 min, washed with H 2 O, scanned, then blocked using 4 % nonfat dry milk, 0.1 % Tween-20, 40 mM Tris, pH 7.5 for 1-2 h. Specified primary antibodies were incubated separately with blots in block buffer for 24 h at 4°C. Immunopositive bands were detected using alkaline phosphatase antirabbit secondary antibody and development with BCIP/NBT. Selected blots were reprobed by 1-2 s re-hydration in methanol, followed by a 30 min incubation in block buffer, then primary antibody incubation and development as described above. For densitometric quantification, dried blots were scanned on an HP Scanjet 4400C scanner and band intensities measured using UN-SCAN-IT software (version 5.1) from Silk Scientific, Inc. (Orem, UT).
Results
Chaetoglobosin K inhibits growth of WB-ras1 and H2009 human lung carcinoma cells
We previously reported that 1 μM ChK inhibited growth of WB-ras1 cells by 70 % on day 2 and 91 % on day 6 compared to vehicle-treated controls [29] . Cell growth of H2009 cells was also inhibited by ChK as shown in Fig. 1 . Treatment with 2 μM ChK significantly reduced H2009 human lung carcinoma cells by 40 % on day 2 and 56 % on day 5 compared to vehicle-treated controls. We previously reported that ChK is non-cytotoxic below 15 μM to WB-ras1 and RG-2 glial cells [29, 30] .
Chaetoglobosin K modulates JNK activation in WB-ras1 and human lung carcinoma cells Figure 2a shows that treatment of WB-ras1 cells with 2 to 10 μM ChK for 24 h decreased phosphorylation of JNK on activation sites thr183/tyr185 in a dose-dependent manner (Top panel, lanes 4-9 compared to vehicle control lanes 2 and 3). Total JNK levels did not change (Second panel from top). Figure 2b shows quantification by densitometric scanning of phospho-JNK levels normalized to total JNK levels, indicating an approximately 85 % decrease in phosphorylation of JNK at 10 μM ChK. Decreased activation of JNK was detectable as early as 4 h post-treatment (Fig. 3a, top panel, lanes 6-7 compared to control lanes 1-2 and quantification in Fig. 3b) .
We also tested whether ChK modulates JNK activation in H2009 human lung carcinoma cells. Results show that 5 μM ChK decreased JNK phosphorylation (Fig. 4a , top panel, lanes 4-5 compared to vehicle control lanes 2-3). Quantification by densitometry (Fig. 4b) indicated an approximately 35 % decrease in phosphorylation of JNK at 24 h treatment compared to controls. At 10 μM ChK, however, phospho-JNK was not significantly different from vehicle-treated controls (Fig. 4a , top panel, lanes 6-7 compared to lanes 2-3 and Fig. 4b) . To see whether a lack of effect at 10 μM ChK occurred in other tumor cells, we treated H1299 lung tumor cells with 5 and 10 μM ChK. The results show that both 5 and 10 μM ChK significantly decreased phospho-JNK levels compared to vehicle-treated controls (Fig. 4c, d ). A more detailed dose-response of ChK's effect on JNK phosphorylation in H2009 cells showed that significant decreased phosphorylation is observed at 5 μM ChK, but not higher concentrations up to 12.5 μM (Fig. 4e) . Total JNK levels were not substantially altered by ChK at 5 or 10 μM ChK in either lung tumor cell type ( Fig. 4a and c, lower panels).
Chaetoglobosin K modulates Akt activation in WB-ras1 and human lung carcinoma cells (Fig. 5d) , and also did not alter total Akt kinase levels (Fig. 5c , bottom panel).
Effect of chaetoglobosin K on downstream effectors of JNK and Akt kinase Figure 6 shows that treatment of WB-ras1 cells for 24 h with 5 or 10 μM ChK decreased phosphorylation on activation sites of two downstream effectors of JNK, c-JUN (a,b) and ATF-2 (c,d), but had no effect on Stat3 phosphorylation on the ser727 activation site (e,f). ChK also decreased phosphorylation of the Akt downstream effectors, MDM2 at the ser166 site (Fig. 6g, h ) and Rac1 on the inhibitory ser71 inhibitory site (Fig. 6i, j) . (Fig. 7a, b) or PDK1 at the autophosphorylation ser241 site (Fig. 7c, d) . Total PTEN and PDK1 levels were similarly unaltered by ChK. ChK likewise had no effect on the level of phosphorylation on key activation sites of two upstream activators of JNK, MKK4 (Fig. 7e, f) and MKK7 (Fig. 7g, h) . Total MKK4 and MKK7 levels were also unaltered by ChK.
Comparative effect of ChK with PI3K inhibitors
Comparison of ChK with known PI3K inhibitors LY294002 and Wortmannin shows that all three decreased phosphorylation of Akt on ser473 (Fig. 8a) . ChK-treated WB-ras1 cells (Fig. 8a, lanes 4-5) show substantially decreased Akt phosphorylation at 24 h compared to vehicle-treated control cells (Fig. 8a, lanes 2-3) . LY294002 and Wortmannin, (Fig. 8a, lanes 6-7 and 8-9 respectively) also decreased phosphorylation of Akt on ser473. Densitometric quantification is shown in Fig. 8b . Figure 8c and d show that only ChK decreased JNK phosphorylation on the thr183/ tyr185 activation sites, however, while LY294002 inhibitory and Wortmannin had no significant effect on JNK phosphorylation compared to controls.
Discussion
The present report demonstrates the dual inhibitory effect of ChK on both Akt and JNK activation in ras-transformed and human lung carcinoma cells in vitro. These key enzymes in the PI3K and JNK MAPK signaling pathways play an important role in cell cycle transition, proliferation, and malignancy [15, 22, 26] . Dual inhibition of MAPK and PI3K pathways has shown synergy in the treatment of ras-mutated lung cancers not responsive to single PI3K inhibition [32] . The simultaneous inhibition of PI3K and MAPK pathways is often achieved through the administration of multiple drugs that target each signaling pathway separately. Therefore, the development of a single agent that can inhibit both PI3K/Akt and JNK MAPK pathways would be of great therapeutic significance. ChK treatment led to decreased activation of the Akt downstream effector, MDM2 (Fig. 6g, h ), as would be expected since Akt activation was decreased. Likewise, ChK treatment led to decreased activation of the JNK downstream effectors, ATF-2 and c-JUN (Fig. 6a-d) . However, the direct upstream activators of JNK, MKK4 or MKK7, were not affected by ChK (Fig. 7e-h ). This lack of effect on the direct upstream MAPKK kinases of JNK, suggest that ChK is not acting on a stress receptor in the MEKK1/4KKK→MKK4/7→JNK signaling pathway to inhibit JNK, but through an alternate mechanism that could be effective in tumors with mutations downstream from the activating receptor. The direct upstream activator of Akt, PDK-1, was not altered at the ser241 autophosphorylation site by ChK treatment (Fig. 7c, d ), but phosphorylation at this site does not definitely determine PDK-1 kinase activity. Likewise, ChK did not alter PTEN phosphorylation on the ser308/thr382,thr383 destabilizing site (Fig. 7a, b) , but activation of PDK-1 via PTEN activation is not the only pathway to Akt activation. Thus, further studies are needed to assess ChK's upstream effects on Akt activation such as direct modulation of Akt by PIP3 [16] and mTOR phosphorylation of Akt on ser473 [33] .
We observed that ChK decreases Rac1 phosphorylation on the ser71 inhibitory site (Fig. 6i, j) in WB-ras1 cells, which would be predicted to lead to Rac1 activation [34] . Rac1 has been reported to be upstream of JNK in some cells [35, 36] , activating JNK via MLK3 [36] . Since we do not see an effect of ChK on MKK4 (Fig. 7e, f) , which is an effector of MLK3 that phosphorylates JNK, we hypothesize that decreased Rac1 phosphorylation by ChK does not crossover to the JNK pathway in our cells. However, the observed decrease in Rac1 phosphorylation on ser71 after ChK treatment which would result in Rac1 activation, is consistent with ChK's inhibitory effect on cytokinesis [29] , since inhibition of Rac1 has been shown to be essential for cytokinesis in other systems [37, 38] .
It is unclear why 10 μM ChK did not alter phosphorylation of JNK, while 5 μM ChK decreased phosphorylation in H2009 cells (Fig. 4a, b) . This differed from H1299 lung tumor cells and WB-ras1 cells where both 5 and 10 μM ChK decreased phosphorylation of JNK (Figs. 4c, d and 2a, b) . It is possible that the higher doses of ChK activated the JNK stress pathway in H2009 cells, but not H1299 or WB-ras1 cells, which overcame the inhibitory effect of ChK on JNK at 5 μM.
Like ChK, the PI3K inhibitors, Wortmannin and LY294002, inhibited Akt phosphorylation on the ser473 activation site (Fig. 8a, b) . However, unlike ChK which inhibited JNK phosphorylation at the Thr183/Tyr185 activation site, Wortmannin and LY294002 had no inhibitory effect or somewhat increased JNK phosphorylation at this site (Fig. 8c, d) . These results are consistent with previous reports showing increased JNK activation in cancer cells treated with Wortmannin and LY294002 [34] . Thus, ChK does not act as a classic PI3K inhibitor, but rather, has unique effects that are more favorable for inhibiting growth of tumor cells with over activated JNK.
We detected no effect of ChK on Stat3 phosphorylation on ser727 in WB-ras1 cells (Fig. 6e, f) or in H2009 cells (unpublished observations). Lim and Cao previously showed that activated JNK phosphorylated Stat3 on ser727 in vitro and that Stat3 was also phosphorylated at this site in vivo by cotransfection of JNK1 with MEKK1 [39] . It is possible that Stat3 does not serve as a target of JNK in non-cotransfected cells, or serves as a target of JNK only in selected cell types that do not include the ones used in this study. Stat3 can also be phosphorylated on tyr705 by JAK, which leads to activation via dimer formation, followed by nuclear translocation [40] . We predict that ChK would not activate Stat3 by tyrosine phosphorylation, as activated Stat3 has anti-apoptotic and oncogenic potential.
Several current targeted tumor therapies such as erlotinib, gefitinib, and cetuximab, target the membrane EGF receptor [5-8, 11, 41] . However, patients with mutations downstream from EGFR, often do not respond well to these therapies. Therefore, inhibitors that target downstream kinases or regulatory molecules in the EGF and other growth signaling pathways are needed for such patients. An example of such a therapy is vemurafenib, which targets Raf and has recently been marketed to treat advanced melanomas [12] . ChK's ability to inhibit Akt and JNK downstream kinases in our model ras-transformed cells as well as human lung tumor cells, suggests that ChK would be effective for some patients with mutations downstream of membrane receptors. The unique dual inhibitory effect of ChK on these two important growth signaling pathways involved in carcinogenesis earmarks ChK for further studies to determine its molecular target(s). 
